Entry

D10525            Mixture   Drug

Name

Valsartan and cilnidipine;
Atedio (TN)

Component

Valsartan [DR:D00400], Cilnidipine [DR:D01173]

Class

Cardiovascular agent
DG01925  Renin-angiotensin system inhibitor
DG03231  Antihypertensive
Metabolizing enzyme substrate
DG01639  CYP2C19 substrate
DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate

Remark

Therapeutic category:

2149

Product:

D10525<JP>

Efficacy

Antihypertensive

Comment

Cilnidipine is metabolized by CYP3A4 with some contribution from CYP2C19.

Metabolism

Enzyme: CYP3A4 [HSA:1576]; CYP2C19 [HSA:1557]

Interaction

Brite

Therapeutic category of drugs in Japan [BR:br08301]
2  Agents affecting individual organs
  21  Cardiovascular agents
   214  Antihypertensives
    2149  Others
     D10525  Valsartan and cilnidipine
Drug groups [BR:br08330]
Cardiovascular agent
  DG01925  Renin-angiotensin system inhibitor
   D10525  Valsartan and cilnidipine
  DG03231  Antihypertensive
   D10525  Valsartan and cilnidipine
Metabolizing enzyme substrate
  DG01639  CYP2C19 substrate
   D10525  Valsartan and cilnidipine
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D10525  Valsartan and cilnidipine
Drug classes [BR:br08332]
Cardiovascular agent
  DG03231  Antihypertensive
   D10525  Valsartan and cilnidipine
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D10525

Other DBs

PubChem:

254741487